Well Referenced

Tag: Myocardial Infarction

Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis

This systematic review and meta-analysis evaluated the safety and efficacy of mesenchymal stem cell (MSC) therapy in adults with acute myocardial infarction (AMI) and ischemic heart failure (IHF). Analyzing 23 clinical trials (11 on AMI and 12 on IHF), the study found that MSC therapy was not associated with acute

Read More »
June 26, 2025 No Comments

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial

The 2013 TACT trial, a double-blind, placebo-controlled study, assessed the efficacy of disodium EDTA chelation therapy in 1,708 patients aged ≥50 years with prior myocardial infarction (MI). Participants received 40 infusions of a chelation solution containing 3 g of disodium EDTA, ascorbate, B vitamins, electrolytes, procaine, and heparin, or placebo.

Read More »
June 26, 2025 No Comments

Increased Cardiovascular Disease Mortality Associated With Excessive Exercise in Heart Attack Survivors

This prospective cohort study evaluated 2,377 myocardial infarction (MI) survivors over a mean follow-up of 10.4 years to examine the relationship between exercise volume and cardiovascular mortality. Findings revealed that moderate physical activity (up to 7.2 MET-hours/day) significantly reduced cardiovascular disease (CVD) mortality, with optimal benefits at 5.4–7.2 MET-h/day. However,

Read More »
June 26, 2025 No Comments

Testosterone Replacement Therapy and Cardiovascular Disease

This review examines the evolving evidence on the cardiovascular safety of testosterone replacement therapy (TRT) in men with hypogonadism. While earlier observational studies raised alarms over increased cardiovascular risks—including myocardial infarction and stroke—recent randomized trials, particularly the TRAVERSE study, provide reassurance that TRT does not significantly increase the risk of

Read More »
June 26, 2025 No Comments

Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

This 2024 systematic review and meta-analysis evaluated the efficacy of cholesteryl ester transfer protein inhibitors (CETPis) in reducing cardiovascular events. Analyzing nine randomized controlled trials conducted between 2003 and 2023, the study found that CETPis significantly reduced cardiovascular disease (CVD)-related mortality (RR = 0.89; 95% CI: 0.81–0.98; p = 0.02)

Read More »
June 26, 2025 No Comments

Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease: Possible Role for Chelation Therapy

This review explores the impact of heavy metal exposure, particularly cadmium and lead, on chronic kidney disease (CKD) and cardiovascular disease (CVD). It highlights that both acute and chronic low-level exposures contribute to renal and cardiovascular toxicity. The article discusses the potential benefits of chelation therapy, specifically with calcium EDTA,

Read More »
June 26, 2025 No Comments

The Trial to Assess Chelation Therapy 2 (TACT2): Rationale and Design

This article presents the design and rationale of the TACT2 trial, a randomized, double-blind, placebo-controlled study aiming to confirm the cardiovascular benefits of EDTA chelation therapy observed in diabetic patients in the original TACT trial. Targeting a high-risk population of 1,200 patients with diabetes and prior myocardial infarction, the trial

Read More »
June 26, 2025 No Comments

EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy

This randomized, double-blind, placebo-controlled, 2×2 factorial trial investigated the independent and combined effects of intravenous disodium EDTA chelation therapy and high-dose oral multivitamins/minerals (OMVM) in 1,708 patients with a history of myocardial infarction. Participants were randomized into four groups receiving: (1) EDTA + OMVM, (2) EDTA + placebo vitamins, (3)

Read More »
June 26, 2025 No Comments